EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSCHYG00000026127
Gene Symbol: SCN9A
1 Cross references
109 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSCHYG00000026222
Gene Symbol: SLC10A2
1 Cross references
211 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSCHYG00000020488
Gene Symbol: SLC18A2
1 Cross references
222 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSCHYG00000019813
Gene Symbol: SLC22A6
1 Cross references
495 Possible Orthologues:

Solute Carrier Family 22 Member 8

Ensembl ID : ENSCHYG00000019926
Gene Symbol: SLC22A8
1 Cross references
304 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSCHYG00000003261
Gene Symbol: SLC29A1
1 Cross references
280 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSCHYG00000001245
Gene Symbol: SLC5A1
1 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSCHYG00000002950
Gene Symbol: SLC5A2
1 Cross references
199 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSCHYG00000019091
Gene Symbol: SLC6A1
1 Cross references
281 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSCHYG00000006837
Gene Symbol: SLC6A2
1 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSCHYG00000007006
Gene Symbol: SLC6A4
1 Cross references
205 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSCHYG00000021986
Gene Symbol: SLC9A3
1 Cross references
238 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).